Mufg Securities Americas Inc. Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mufg Securities Americas Inc. bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,554 shares of the biopharmaceutical company's stock, valued at approximately $1,107,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Nissay Asset Management Corp Japan ADV raised its position in shares of Regeneron Pharmaceuticals by 3.6% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 24,125 shares of the biopharmaceutical company's stock valued at $17,187,000 after buying an additional 847 shares in the last quarter. NorthRock Partners LLC raised its position in shares of Regeneron Pharmaceuticals by 90.0% during the 4th quarter. NorthRock Partners LLC now owns 802 shares of the biopharmaceutical company's stock valued at $571,000 after buying an additional 380 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Regeneron Pharmaceuticals by 2.1% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 82,519 shares of the biopharmaceutical company's stock valued at $58,774,000 after buying an additional 1,712 shares in the last quarter. Mmbg Investment Advisors CO. purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $264,000. Finally, Lazard Asset Management LLC raised its position in shares of Regeneron Pharmaceuticals by 22.8% during the 4th quarter. Lazard Asset Management LLC now owns 19,912 shares of the biopharmaceutical company's stock valued at $14,183,000 after buying an additional 3,696 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Bank of America lowered their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research report on Thursday, April 17th. TD Cowen lowered their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a research report on Tuesday, February 4th. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Bernstein Bank reduced their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Guggenheim reduced their target price on shares of Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $890.60.

Regeneron Pharmaceuticals Trading Up 1.6%

Shares of NASDAQ:REGN traded up $9.33 on Friday, hitting $594.32. The company had a trading volume of 935,531 shares, compared to its average volume of 789,938. Regeneron Pharmaceuticals, Inc. has a 1 year low of $520.50 and a 1 year high of $1,211.20. The firm has a market capitalization of $64.17 billion, a price-to-earnings ratio of 15.53, a P/E/G ratio of 2.34 and a beta of 0.43. The firm's 50-day simple moving average is $599.96 and its two-hundred day simple moving average is $682.98. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same period last year, the business earned $9.55 earnings per share. The company's revenue was down 3.7% on a year-over-year basis. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.59%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.